BACKGROUND: Vascular calcification contributes to increased cardiovascular morbidity and mortality in patients with chronic kidney disease, diabetes, and atherosclerosis. Currently, there are no effective therapeutic strategies to prevent or reverse vascular calcification. TRPV4 (transient receptor potential channel V4), a key Ca 2+ -permeable channel, plays an important role in various diseases. However, the role and mechanism of TRPV4 in vascular calcification have not yet been elucidated. METHODS: The effects of TRPV4 on vascular calcification were explored in vitro and in vivo. TRPV4 interactome assessment and molecular docking were performed to investigate the mechanism and specific therapeutic strategy for vascular calcification. RESULTS: TRPV4 was substantially upregulated in high inorganic phosphate–induced calcified vascular smooth muscle cells (SMCs) and calcified aortas from cholecalciferol (vitamin D3)-overloaded mice. TRPV4 overexpression increased the expression of the osteochondrogenic markers Runx2 (runt-related transcription factor 2), Msx2 (Msh homeobox 2), and Sox9 (SRY-box transcription factor 9) and exacerbated high inorganic phosphate–induced vascular SMC calcification in a Ca 2+ influx–dependent manner. In contrast, TRPV4 deficiency or inactivation significantly inhibited vascular SMC calcification under high inorganic phosphate conditions. Moreover, compared with that in control littermates, SMC-specific TRPV4 deficiency in mice alleviated vitamin D3–induced and 5/6 nephrectomy–induced vascular calcification. Mechanistically, TRPV4 interacted with β-catenin and activated β-catenin/TCF (T-cell factor) transcriptional activity via Ca 2+ /ASK1 (apoptosis signal regulating kinase 1)/p38 signaling. β-Catenin knockdown abolished the effects of TRPV4 overexpression on vascular SMC calcification. TRPV4/β-catenin interaction is pivotal for maintaining TRPV4/Ca 2+ -induced ASK1/p38/β-catenin activation. Hesperidin, a natural product found in citrus fruits, effectively disrupted TRPV4/β-catenin interaction, thereby inhibiting ASK1/p38/β-catenin activity and preventing vascular calcification. CONCLUSIONS: Our study identified TRPV4 as a new pathogenic factor for vascular calcification that directly associates with and activates β-catenin. Blocking the TRPV4/β-catenin interaction through hesperidin suppressed the progression of vascular calcification and may be an effective precision strategy to address vascular calcification.
20 October 2026 in Journal of the American Heart Association
Background: Thoracic aortic dissection (TAD) is a life‐threatening vascular disease that lacks effective pharmacological treatment. Canonical transient receptor potential (TRPC) channels are involved in regulating various cardiovascular functions, yet their roles in TAD have not been elucidated. Methods: Three‐week‐old male mice were administered β‐aminopropionitrile dissolved in drinking water for 28 days to induce TAD formation. The effects of TRPCs on TAD were explored in vitro and in vivo. RNA sequencing of thoracic aortas was performed to investigate the mechanism by which TRPCs regulate TAD progression. Results: Among the TRPC family members, TRPC1 expression was markedly increased in aortas from β‐aminopropionitrile–induced TAD mice along with the downregulation of the vascular smooth muscle cell (SMC) contractile markers smooth muscle α‐actin and smooth muscle 22. Compared with control littermates, SMC‐specific TRPC1 deficiency in mice alleviated β‐aminopropionitrile–induced TAD formation characterized by decreased aortic rupture, reduced maximal thoracic aortic diameters, and less elastin degradation. Conversely, SMC‐specific knock‐in of TRPC1 exacerbated TAD development in mice. Unbiased RNA sequencing showed that TRPC1 knockout in vascular SMCs inhibited the expression of inflammatory factors and chemokines in thoracic aortas during the early stage of β‐aminopropionitrile administration. Mechanistically, TRPC1 induced the proinflammatory phenotypic transition of vascular SMCs by activating the calcineurin/nuclear factor‐κB pathway, thereby contributing to vascular inflammation and TAD development. Conclusions: Our study identified TRPC1 as a novel endogenous pathogenic factor for vascular SMC inflammatory phenotypic transition and TAD formation and provided new insights for a comprehensive understanding of the mechanisms during TAD. Blocking the TRPC1/calcineurin/nuclear factor‐κB signaling suppressed TAD progression, which may be a promising strategy to address TAD.